Order results by:
| Issue | Title | |
| Vol 14, No 1 (2021) | Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District | Abstract similar documents |
| M. S. Soboleva, E. E. Loskutova | ||
| "... combinations of -blockers in the price range of 100-500 rubles: atenolol+chlortalidone; bisoprolol+amlodipine ..." | ||
| Vol 18, No 2 (2025) | Population consumption of antihypertensive and lipid-lowering drugs in the Russian Federation (SPARDEC) | Abstract similar documents |
| Zh. D. Kobalava, I. K. Petrukhina, P. A. Lebedev, P. R. Blinkova, T. K. Ryazanova, E. P. Gladunova, E. V. Paranina | ||
| "... positions are held by amlodipine (13.6%), enalapril (11.6%), and indapamide (9.7%). Among FDCs, the most ..." | ||
| Vol 9, No 2 (2016) | METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY | Abstract similar documents |
| N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov | ||
| "... for regorafenib was estimated at 111,500 rubles per month and is the lowest among the alternatives: 136,000 rubles ..." | ||
| Vol 9, No 2 (2016) | PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA | Abstract similar documents |
| N. A. Avxentyev, M. Yu. Frolov | ||
| "... ,7 billion rubles (500 million rubles less than for second best option), and government reimbursement costs ..." | ||
| Vol 10, No 3 (2017) | Evaluation of economic damage from multiple sclerosis in the city of Ufa, Russia | Abstract similar documents |
| E. V. Ivanova, K. Z. Bachtiyarova | ||
| "... 428,222,026.35 rubles per year, mostly due to direct medical costs; of those, almost 50% is spent ..." | ||
| Vol 11, No 3 (2018) | Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus | Abstract similar documents |
| A. G. Tolkushin, N. L. Pogudina | ||
| "... in patient survival. The total costs for belimumab vs standard therapy approximated 8.84 million rubles vs 17 ..." | ||
| Vol 8, No 2 (2015) | PHARMACOECONOMIC STUDIES TREATMENT OF PATIENTS WITH INJURIES IN THE DEPARTMENT OF ANESTHESIOLOGY AND RESUSCITATION WITH METHODS ANALYSIS THE COST OF ILLNESS | Abstract similar documents |
| Anton Alexandrovich Kasatkin | ||
| "... with the severity of the injury 31 points and made 11 000 and 5600 rubles. respectively. The cost of treating ..." | ||
| Vol 12, No 2 (2019) | Comparative modeling of socio-economic burden among smokers, nonsmokers and former smokers | Abstract similar documents |
| E. V. Radchenko, A. S. Kolbin | ||
| "... disability) was 510.6 billion rubles. The difference between the smokers and the equal-sized non-smoking ..." | ||
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of antiretroviral therapy regimes in the Syrian Arab Republic | Abstract similar documents |
| Yu. Sh. Gushchina, А. Yu. Abramov, Y. J. Haitham | ||
| "... prices in rubles, currency conversion was carried out as of January 1, 2021. To calculate the cost ..." | ||
| Vol 5, No 3 (2012) | CLINICAL AND ECONOMIC BENEFITS OF HUMAN INSULIN ANALOGUESUSE | Abstract similar documents |
| E. E. Arinina, M. A. Rashyd | ||
| "... ®) were 21774 rubles per patient/year, while the cost of an averted severe hypoglycemia was 24728 rubles ..." | ||
| Vol 17, No 2 (2024) | Cost-effectiveness analysis of acalabrutinib in treatment of patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy | Abstract similar documents |
| S. K. Zyryanov, I. N. Dyakov | ||
| "... for acalabrutinib were 3,546,237,60 rubles, for ibrutinib – 5,591,391,00 rubles (a difference of 2,045,153,40 rubles ..." | ||
| Vol 8, No 4 (2015) | THE COST OF NUTRITION ALTERNATIVES FOR PREMATURE INFANTS IN RUSSIA | Abstract similar documents |
| K. V. Gerasimova, M. V. Avxentyeva, I. A. Belyaeva | ||
| "... .14 rubles, respectively). The cost per averted case of NE was 21 115 rubles within 35 days that is less than ..." | ||
| Vol 17, No 2 (2024) | Clinical and economic assessment of using IRS®19 for the treatment and prevention of acute respiratory infections in children | Abstract similar documents |
| A. S. Kolbin, A. R. Kasimova | ||
| "... . The total costs of the healthcare system and the state for 1 AVI patient are 42,472 rubles in case ..." | ||
| Vol 16, No 3 (2023) | Comparative analysis of using atezolizumab vs. durvalumab in combination with platinum-containing chemotherapy in adult patients with advanced small cell lung cancer | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova | ||
| "... (2,310,546.07 rubles) were significantly lower than for the CP/EP + Durv course (4,081,833.98 rubles ..." | ||
| Vol 7, No 3 (2014) | ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva | ||
| "... orphan diseases were 15.73 bln rubles per year (6.36 bln rubles for children and 9.37 bln rubles ..." | ||
| Vol 18, No 1 (2025) | Pharmacoeconomic analysis of lanreotide and prolonged-release octreotide in first- and second-line therapy of acromegaly | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova, D. V. Kurkin | ||
| "... of lanreotide amounted to 1,466,669.49 rubles per patient with acromegaly compared to 908,272.53 rubles ..." | ||
| Vol 8, No 2 (2015) | CLINICAL AND ECONOMIC ANALYSIS OF THE USE OF DIFFERENT TYPES OF SYSTEMS OF VENOUS ACCESS IN THE TREATMENT OF CHILDREN WITH CANCER | Abstract similar documents |
| Maksim Yur'evich Rykov, Vladimir Georgievich Polyakov | ||
| "... of treatment five subclavian catheters necessary to spend 227.25 mln. rubles. And the implantations of venous ..." | ||
| Vol 16, No 2 (2023) | Comparative pharmacoeconomic analysis of follitropin delta application for superovulation induction during artificial insemination | Abstract similar documents |
| I. S. Krysanov, V. S. Krysanova, V. Yu. Ermakova | ||
| "... amounted to 132,123.99 rubles with the use of follitropin delta, and 133,392.19 rubles with the use ..." | ||
| Vol 12, No 2 (2019) | Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria | Abstract similar documents |
| S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova | ||
| "... with ceftazidime + avibactam amounted to 228.3 thousand rubles, which was lower than the cost of using ..." | ||
| Vol 15, No 2 (2022) | Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings | Abstract similar documents |
| M. V. Zhuravleva, S. N. Avdeev, Yu. V. Gagarina, T. V. Marin | ||
| "... for benralizumab therapy in the hospital settings and amounted to 0.99 million rubles versus 1.17 million rubles ..." | ||
| Vol 16, No 3 (2023) | Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable BRAF V600-mutated metastatic melanoma in Russia | Abstract similar documents |
| N. A. Avxentyev, Yu. V. Makarova | ||
| "... of treatment as the disease progresses, was 6,547,693.07 rubles. Meanwhile, it was 5,962,742.52 rubles ..." | ||
| Vol 17, No 2 (2024) | Clinical and economic assessment of using topical bacterial lysate Imudon® for the treatment and prevention of acute upper respiratory tract infections in children | Abstract similar documents |
| A. R. Kasimova, A. S. Kolbin | ||
| "... the entire childcare period. Results. GDP per capita for 2022 amounted to 2853.13 rubles per day. Thus ..." | ||
| Vol 16, No 1 (2023) | Efficiency of Levilimab in patients with moderate and severe COVID-19 | Abstract similar documents |
| Yu. M. Gomon, V. V. Strizheletsky, I. G. Ivanov, Yu. E. Balykina, M. V. Ermolyev, A. S. Kolbin, M. V. Livshits, T. A. Usmanova, A. M. Fakhrutdinova, Yu. S. Konstantinova, A. P. Gubanov | ||
| "... disease was 54 665.30 rubles, with severe disease – 91 285.85 rubles. The estimated cost of the additional ..." | ||
| Vol 15, No 1 (2022) | Pharmacoeconomic analysis of using Monofer in patients with iron deficiency anemia as part of the provision of medical care under the state guarantees program in the health care system of the Russian Federation | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, V. G. Serpik, O. A. Gromova, I. Yu. Torshin | ||
| "... was 13,097 rubles for Monofer and 15,681 rubles for Ferinject®. The values of the cost-effectiveness ..." | ||
| Vol 15, No 3 (2022) | Long-term analysis of сanagliflozin budget impact in adult patients with type 2 diabetes mellitus and diabetic nephropathy in the Russian Federation | Abstract similar documents |
| N. A. Avxentyev, Yu. V. Makarova | ||
| "... receiving canagliflozin therapy were 678 108 rubles, which was 52.8% (759,239 rubles) lower than without ..." | ||
| Vol 12, No 4 (2019) | Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation | Abstract similar documents |
| S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev | ||
| "... the competitors. To prevent asthma exacerbations by omalizumab requires 463 805 rubles, which is 24.80% less than ..." | ||
| Vol 14, No 2 (2021) | Clinical and economic analysis of using the thrombodynamics test in patients undergoing treatment with assisted reproductive technologies in the Russian Federation | Abstract similar documents |
| D. G. Shchurov, V. S. Dombrovskiy | ||
| "... scenario. The smallest ICER values were observed in Scenario 2, and amounted to 112,120 rubles for 1 child ..." | ||
| Vol 9, No 3 (2016) | METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL | Abstract similar documents |
| O. V. Zhukova, S. V. Kononova | ||
| "... for Sumamed (Teva), and it amounted to 39 367.50 rubles. Sumamed was characterized by the highest clinical ..." | ||
| Vol 11, No 2 (2018) | Clinical and economic efficiency of the loop ileostomy closure by various methods | Abstract similar documents |
| A. V. Veselov, S. I. Achkasov, O. I. Sushkov, A. I. Moskalev, I. S. Lantsov | ||
| "... ,704.90 rubles. and 145,473.70 rubles, respectively, while in group 3, the cost was higher – 167,443,60 rubles (p ..." | ||
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy | Abstract similar documents |
| M. V. Zhuravleva, V. P. Chulanov, Yu. V. Gagarina, E. A. Shabalina | ||
| "... in additional 0.2657 LIGs or 0.2255 QALYs. The cost of 1 LIG was 213,4 thousand rubles, the cost of 1 QALY ..." | ||
| Vol 16, No 3 (2023) | Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study | Abstract similar documents |
| A. S. Kolbin, Yu. M. Gomon, M. A. Proskurin, Yu. E. Balykina | ||
| "... for alectinib (12,551,770 and 7,451,522 rubles, respectively). At the same time, the difference was mainly ..." | ||
| Vol 10, No 2 (2017) | CLINICAL AND ECONOMIC EVALUATION OF CHRONIC DISEASE TREATMENT: A DISCREPANCY BETWEEN THE TRADITIONAL PHARMACOECONOMIC AND SOCIO-ECONOMIC ANALYSES | Abstract similar documents |
| O. V. Zhukova, S. V. Kononova | ||
| "... in medical costs from 873.00 rubles to 1515.39 rubles, and to a decrease in the average number ..." | ||
| Vol 11, No 3 (2018) | Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies | Abstract similar documents |
| T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov | ||
| "... ,878.21 rubles, and the cost of one additionally saved QALY – 365,060.31 rubles. Conclusion. The WTPT ..." | ||
| Vol 17, No 3 (2024) | Economic analysis of implementing Systemic Coronary Risk Estimation (SCORE2) scale and long-term consequences | Abstract similar documents |
| E. O. Kurilovich, A. V. Nikitina, I. V. Sorokovikov | ||
| "... .18 billion rubles (with government funding) to 318.14 billion rubles. Concurrently, pharmacocorrection ..." | ||
| Vol 12, No 4 (2019) | Optimization of drug supply for patients with malignant neoplasms in a region of the Russian Federation | Abstract similar documents |
| A. V. Nikitina, F. V. Gorkavenko, Y. S. Saybel, M. V. Avxentyeva, M. S. Sura, D. V. Fedyaev | ||
| "... the costs of drugs for solid tumors at the 352.2 million rubles for 5 years (baseline scenario), 69 ..." | ||
| Vol 13, No 4 (2020) | Pharmacoeconomic analysis of first-choice antimicrobial drugs prescribed for outpatient treatment of non-severe community-acquired pneumonia | Abstract similar documents |
| V. G. Deriushkin, A. P. Ternavskii, S. V. Gatsura | ||
| "... was worth 617.50 rubles. A comparison of the calculated average actual and simulated average AMDs course ..." | ||
| Vol 16, No 4 (2023) | Analysis of the clinical and economic effectiveness of using benralizumab in comparison with standard therapy in patients with severe bronchial asthma | Abstract similar documents |
| S. V. Nedogoda, A. S. Salasyuk, S. N. Avdeev, I. N. Barykina, V. O. Lutova, E. A. Popova | ||
| "... . It will provide avoiding 4.95 exacerbations, simultaneously with a reduction in total costs by 584,144 rubles ..." | ||
| Vol 18, No 1 (2025) | Reorganization of public procurement of biosimilars and its economic effect on the monoclonal antibody market in Russia | Abstract similar documents |
| A. Yu. Efremov, A. M. Vlasov, V. I. Gegechkori, N. V. Gorpinchenko, G. V. Ramenskaya, T. M. Litvinova | ||
| "... and pembrolizumab biosimilars, resulting in savings of 15.1 and 3.8 billion rubles, respectively. In the group ..." | ||
| Vol 10, No 2 (2017) | COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD | Abstract similar documents |
| E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov | ||
| "... groups amounted to 32,753 rubles and 37,641 rubles, respectively. Thus, the savings of using the combined ..." | ||
| Vol 11, No 1 (2018) | Antimicrobial therapy of community-acquired pneumonia in a hospital setting (clinical and economic aspects) | Abstract similar documents |
| O. V. Zhukova, O. V. Ruina, M. V. Khazov, S. V. Romanov | ||
| "... of moderate CAP were: 10.5 days and 731.65 rubles for ceftriaxone; 9.1 days and 1353.00 rubles ..." | ||
| Vol 14, No 2 (2021) | Pharmacoeconomic aspects of oral vinorelbine application: a budget impact analysis considering the new registered price | Abstract similar documents |
| D. A. Ivanov, I. N. Dyakov, S. K. Zyryanov | ||
| "... vinorelbine provides financial savings for a medical organization at the amount of 246,042.34 rubles per 6 ..." | ||
| Vol 14, No 2 (2021) | Organizational and economic aspects of triplet therapy of relapsed/refractory multiple myeloma in the Russian healthcare setting | Abstract similar documents |
| E. A. Pyadushkina, E. V. Derkach, V. I. Ignatyeva, E. E. Yagnenkova, T. Yu. Klitochenko, T. V. Shelekhova, A. N. Levanov | ||
| "... patient in the case of centralized procurement of drugs ranged from 5.51 million rubles (regimen ..." | ||
| Vol 10, No 3 (2017) | Initiation and intensification of insulin therapy in patients with type 2 diabetes mellitus: a budget impact analysis | Abstract similar documents |
| E. V. Biryukova, V. I. Ignat’eva | ||
| "... insulin for the model population of 1,000 patients was 22.5 million rubles. If the use of ready-made ..." | ||
| Vol 11, No 2 (2018) | Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia | Abstract similar documents |
| N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov | ||
| "... approval process. Results. The average medical cost (per year) for nilotinib (1 683 thousand rubles or US ..." | ||
| Vol 16, No 4 (2023) | Socio-economic burden of respiratory syncytial viral infection of the lower respiratory tract in children aged from birth to 5 years in the Russian Federation: modeling results | Abstract similar documents |
| V. I. Ignatyeva, D. Yu. Ovsyannikov, A. E. Tsygankov, E. E. Yagnenkova, V. R. Amirova, M. M. Maryanyan, A. S. Mokrova | ||
| "... . Medical costs for treatment exceed 2.2 billion rubles, and the damage to GDP as a result of lethal ..." | ||
| Vol 16, No 4 (2023) | Pharmacoeconomic analysis of using empegfilgrastim for the treatment of early and locally advanced HER2+ breast cancer in the Russian Federation | Abstract similar documents |
| M. V. Zhuravleva, K. A. Kokushkin, E. A. Luchinin, E. V. Luchinina, T. R. Kameneva, E. V. Kuznetsova, V. S. Krysanova, E. V. Makarova, L. G. Zhukova | ||
| "... to filgrastim (249 vs. 134 thousand rubles), due to the higher rate of achieving a pathomorphological complete ..." | ||
| Vol 17, No 1 (2024) | Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients | Abstract similar documents |
| О. I. Ivakhnenko, V. V. Ryazhenov, N. A. Falaleeva | ||
| "... in 1st line therapy was 8.95 mln rubles for (Dara+Rd)+(K+Rd)+(Pom+dex) and 8.41 mln rubles for (Dara+Rd ..." | ||
| Vol 5, No 3 (2012) | PHARMACOECONOMIC EVALUATION OF TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS ON DIALYSIS WITH CINACALCET | Abstract similar documents |
| R. I. Yagudina, V. G. Serpik | ||
| "... was 20,709 rubles. (Taking into account the costs of dialysis treatments), and for standard therapy - 110 ..." | ||
| Vol 8, No 4 (2015) | ABC-, VEN- AND FREQUENCY ANALYSIS OF TREATMENT OF ATRIAL FIBRILLATION IN OUTCOME PATIENTS | Abstract similar documents |
| A. N. Korobeynikova, S. V. Malchikova | ||
| "... . For the treatment of patient with atrial fibrillation it spends an average of 11245.2 rubles per patient ..." | ||
| Vol 10, No 1 (2017) | EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... with sorafenib or lenvatinib was 7 285 716.92 rubles or 3 368 077.62 rubles, respectively. ..." | ||
| 1 - 50 of 122 Items | 1 2 3 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
